Clear Cell Renal Cell Carcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Kidney Medullary Carcinoma (96)

›

No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline bevacizumab + pegylated interferon α -2a Sensitive : A2	bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline bevacizumab + pegylated interferon α -2a Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A2 - Guideline nivolumab + cabozantinib tablet Sensitive : A2	nivolumab + cabozantinib tablet Sensitive: A2 - Guideline nivolumab + cabozantinib tablet Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	tivozanib Sensitive: A2 - Guideline tivozanib Sensitive : A2	tivozanib Sensitive: A2 - Guideline tivozanib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	Immunotherapy Sensitive: A2 - Guideline Immunotherapy Sensitive : A2	Immunotherapy Sensitive: A2 - Guideline Immunotherapy Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	VEGFR inhibitor Sensitive: A2 - Guideline VEGFR inhibitor Sensitive : A2	VEGFR inhibitor Sensitive: A2 - Guideline VEGFR inhibitor Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	Immunotherapy + VEGFR inhibitor Sensitive: A2 - Guideline Immunotherapy + VEGFR inhibitor Sensitive : A2	Immunotherapy + VEGFR inhibitor Sensitive: A2 - Guideline Immunotherapy + VEGFR inhibitor Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	Immunotherapy + Tyrosine kinase inhibitor Sensitive: A2 - Guideline Immunotherapy + Tyrosine kinase inhibitor Sensitive : A2	Immunotherapy + Tyrosine kinase inhibitor Sensitive: A2 - Guideline Immunotherapy + Tyrosine kinase inhibitor Sensitive : A2
PD-L1 expression	Clear Cell Renal Cell Carcinoma	PD-L1 expression	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: B - Late Trials pembrolizumab + axitinib Sensitive : B	pembrolizumab + axitinib Sensitive: B - Late Trials pembrolizumab + axitinib Sensitive : B
PBRM1 mutation	Clear Cell Renal Cell Carcinoma	PBRM1 mutation	Clear Cell Renal Cell Carcinoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	AVB-500 Sensitive: B - Late Trials AVB-500 Sensitive : B	AVB-500 Sensitive: B - Late Trials AVB-500 Sensitive : B
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials nivolumab + ipilimumab + cabozantinib tablet Sensitive : B	nivolumab + ipilimumab + cabozantinib tablet Sensitive: B - Late Trials nivolumab + ipilimumab + cabozantinib tablet Sensitive : B
VHL mutation	Clear Cell Renal Cell Carcinoma	VHL mutation	Clear Cell Renal Cell Carcinoma	belzutifan Sensitive: C1 - Off-label belzutifan Sensitive : C1	belzutifan Sensitive: C1 - Off-label belzutifan Sensitive : C1
PD-L1 expression	Clear Cell Renal Cell Carcinoma	PD-L1 expression	Clear Cell Renal Cell Carcinoma	nivolumab + ipilimumab Sensitive: C1 - Off-label nivolumab + ipilimumab Sensitive : C1	nivolumab + ipilimumab Sensitive: C1 - Off-label nivolumab + ipilimumab Sensitive : C1
VHL mutation	Clear Cell Renal Cell Carcinoma	VHL mutation	Clear Cell Renal Cell Carcinoma	MK-3795 Sensitive: C2 – Inclusion Criteria MK-3795 Sensitive : C2	MK-3795 Sensitive: C2 – Inclusion Criteria MK-3795 Sensitive : C2
SETD2 mutation	Clear Cell Renal Cell Carcinoma	SETD2 mutation	Clear Cell Renal Cell Carcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
ERVE-4 expression	Clear Cell Renal Cell Carcinoma	ERVE-4 expression	Clear Cell Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
SYNE1 mutation	Clear Cell Renal Cell Carcinoma	SYNE1 mutation	Clear Cell Renal Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3

Clear Cell Renal Cell Carcinoma

Associations(93)

Associations
(93)